Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2005 1
2006 2
2008 3
2009 3
2010 2
2011 2
2013 5
2014 3
2017 1
2018 2
2019 2
2020 1
2021 1
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).
Cornberg M, Stoehr A, Naumann U, Teuber G, Klinker H, Lutz T, Möller H, Hidde D, Lohmann K, Simon KG. Cornberg M, et al. Among authors: teuber g. Viruses. 2022 Jul 14;14(7):1541. doi: 10.3390/v14071541. Viruses. 2022. PMID: 35891520 Free PMC article.
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Stein K, Stoehr A, Klinker H, Teuber G, Naumann U, John C, Heyne R, Serfert Y, Niederau C, Zeuzem S, Berg T, Wiegand J; German Hepatitis C-Registry. Stein K, et al. Among authors: teuber g. Eur J Gastroenterol Hepatol. 2022 Jan 1;34(1):76-83. doi: 10.1097/MEG.0000000000001923. Eur J Gastroenterol Hepatol. 2022. PMID: 32956186
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Vermehren J, Serfert Y, Cornberg M, Stoehr A, Klinker H, Simon KG, Teuber G, Deterding K, Schulze Zur Wiesch J, Jung MC, Manns MP, Zeuzem S, Wedemeyer H, Sarrazin C. Vermehren J, et al. Among authors: teuber g. Z Gastroenterol. 2020 Sep;58(9):841-846. doi: 10.1055/a-1217-7669. Epub 2020 Sep 18. Z Gastroenterol. 2020. PMID: 32947629 English.
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, König B, Pangerl A, Niederau C. Berg T, et al. Among authors: teuber g. Aliment Pharmacol Ther. 2019 Apr;49(8):1052-1059. doi: 10.1111/apt.15222. Epub 2019 Mar 15. Aliment Pharmacol Ther. 2019. PMID: 30874328
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group. Traussnigg S, et al. Among authors: teuber g. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):781-793. doi: 10.1016/S2468-1253(19)30184-0. Epub 2019 Jul 22. Lancet Gastroenterol Hepatol. 2019. PMID: 31345778 Clinical Trial.
34 results